Adamas is a fully-integrated company with deep expertise in the development and commercialization of neurological therapies.
Total raised: $40M
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | DAG Ventur... | dagventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.08.2009 | - | $40M | - |
Mentions in press and media 14
| Date | Title | Description |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 23.11.2021 | Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer | ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supern... |
| 12.10.2021 | Adamas Pharmaceuticals : Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - Form 8-K | Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio October 11, 2021 n Acquisition of two marketed products diversifies and accelerates revenue and cash flow n Expected to be significantly accr... |
| 11.10.2021 | Adamas Pharmaceuticals : Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio | Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastru... |
| 12.05.2021 | Adamas Pharmaceuticals : First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 (Form... | First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 EMERYVILLE, Calif., May 10, 2021 --Adamas Pharmaceuticals, Inc. (Nasda... |
| 12.05.2021 | ADAMAS PHARMACEUTICALS, INC. Adamas Pharmaceuticals : First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase... | First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 EMERYVILLE, Calif., May 10, 2021 --Adamas Pharmaceuticals, Inc. (Nasda... |
| 01.03.2021 | Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares | EMERYVILLE, Calif.--(BUSINESS WIRE)--Mar 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today ... |
| 24.02.2021 | Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering | EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 24, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today... |
| 11.05.2017 | Astellas dumps a PhIII lung cancer drug; GSK gets one success, one failure in a pair of pivotal Crohn’s trials | → Japan’s Astellas Pharma is punting its Phase III drug ASP8273, halting the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the 1st line treatment metastatic or advanc... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
Show more